# Acute Psychosis as the Sole Initial Manifestation of Systemic Lupus Erythematosus: A Diagnostic Challenge

**Authors:** Airenakho Emorinken, Patrick O Adunbiola, Mercy O Dic-Ijiewere, Mojeed O Rafiu, Ndidi N Akerele

PMC · DOI: 10.7759/cureus.102002 · Cureus · 2026-01-21

## TL;DR

A young woman with no prior medical history developed psychosis as the first sign of lupus, highlighting the need to consider autoimmune causes in similar cases.

## Contribution

This case report highlights the rare occurrence of acute psychosis as the sole initial manifestation of SLE and emphasizes the importance of early immunosuppressive treatment.

## Key findings

- Acute psychosis can be the first and isolated manifestation of systemic lupus erythematosus.
- Early immunosuppressive therapy can lead to rapid and sustained resolution of psychotic symptoms in lupus patients.
- Autoimmune testing and exclusion of other causes are crucial in diagnosing lupus-related psychosis.

## Abstract

Neuropsychiatric systemic lupus erythematosus (NPSLE) represents one of the most complex and heterogeneous manifestations of systemic lupus erythematosus (SLE). Psychosis is an uncommon but severe feature of NPSLE and usually occurs in the setting of established multisystem disease. Acute psychotic presentation as the sole initial manifestation of SLE is exceptionally rare and poses considerable diagnostic challenges. We report the case of a 24-year-old woman with no prior psychiatric or medical history who developed abrupt-onset psychosis characterized by insomnia, aggression, persecutory delusions, and auditory hallucinations. Initial evaluation suggested first-episode psychosis; however, poor response to antipsychotic therapy and the presence of unexplained pancytopenia with elevated inflammatory markers prompted further investigation. Autoimmune testing revealed high-titer antinuclear antibodies, elevated anti-double-stranded DNA, anti-Smith, and anti-ribosomal P antibodies, hypocomplementemia, and a positive direct Coombs test. Infectious, metabolic, toxic, and structural neurological causes were systematically excluded. The patient fulfilled the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology classification criteria for SLE and met diagnostic attribution for lupus psychosis. Treatment with high-dose pulse intravenous methylprednisolone and intravenous cyclophosphamide resulted in rapid and sustained resolution of psychotic symptoms, with normalization of laboratory abnormalities. Acute psychosis may rarely be the first and isolated manifestation of SLE. This case highlights the importance of considering NPSLE in young patients presenting with first-episode psychosis and underscores the role of early immunosuppressive therapy in achieving favorable outcomes, even in resource-limited settings.

## Linked entities

- **Diseases:** systemic lupus erythematosus (MONDO:0007915), psychosis (MONDO:0005485)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, BTG3 (BTG anti-proliferation factor 3) [NCBI Gene 10950] {aka ANA, ANA/BTG3, APRO4, TOB5, TOB55, TOFA}
- **Diseases:** infarct (MESH:D007238), serositis (MESH:D012700), Acute Psychosis (MESH:D011605), aggression (MESH:D010554), malaria (MESH:D008288), immune dysregulation (OMIM:614878), human immunodeficiency virus (MESH:D015658), central nervous system infections (MESH:D002494), hydrocephalus (MESH:D006849), cognitive dysfunction (MESH:D003072), movement disorders (MESH:D009069), arthritis (MESH:D001168), metabolic encephalopathies (MESH:D001928), auditory hallucinations (MESH:D006212), microvascular injury (MESH:D017566), nervous system injury (MESH:D020196), altered level of consciousness (MESH:D003244), brain lesions (MESH:D001927), delusions (MESH:D063726), infection (MESH:D007239), immunologic abnormalities (MESH:D007154), neuropsychiatric involvement (MESH:C000631768), Psychosis (MESH:D011618), cerebrovascular disease (MESH:D002561), arthralgia (MESH:D018771), cutaneous rashes (MESH:D005076), intracranial hemorrhage (MESH:D020300), alopecia (MESH:D000505), autoimmune (MESH:D001327), neuropsychiatric manifestations (MESH:D012877), nephritis (MESH:D009393), hypoalbuminemia (MESH:D034141), neurological deficits (MESH:D009461), seizures (MESH:D012640), fever (MESH:D005334), mood and anxiety disorders (MESH:D001008), Lupus psychosis (MESH:D008180), systemic disease (MESH:D034721), vomiting (MESH:D014839), disorganized (MESH:D012562), multisystem disease (MESH:D004194), neurological conditions (MESH:D019636), inflammation (MESH:D007249), headache (MESH:D006261), oral ulcers (MESH:D019226), syphilis (MESH:D013587), autoimmune encephalitides (MESH:D020274), head trauma (MESH:D006259), vasculopathic changes (MESH:D009402), behavioral disturbance (MESH:D001523), NPSLE (MESH:D020945), insomnia (MESH:D007319), pancytopenia (MESH:D010198), lupus nephritis (MESH:D008181), hepatitis B and C (MESH:D006509), neuroinflammatory (MESH:D000090862)
- **Chemicals:** Steroid (MESH:D013256), amphetamines (MESH:D000662), ribosomal P (-), prednisolone (MESH:D011239), HCQ (MESH:D006886), benzodiazepines (MESH:D001569), cocaine (MESH:D003042), rituximab (MESH:D000069283), methylprednisolone (MESH:D008775), promethazine (MESH:D011398), risperidone (MESH:D018967), cyclophosphamide (MESH:D003520), haloperidol (MESH:D006220), mycophenolate mofetil (MESH:D009173), oxygen (MESH:D010100), azathioprine (MESH:D001379)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922866/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12922866/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922866/full.md

---
Source: https://tomesphere.com/paper/PMC12922866